Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Neurobiol Dis. 2019 Nov;131:104428. doi: 10.1016/j.nbd.2019.03.016. Epub 2019 Mar 20.
With the movement toward precision medicine in healthcare, recent studies of individuals with psychosis have begun to explore positron emission tomography (PET) as a tool to test for biochemical signatures that may distinguish subtypes of psychosis that guide subtype-specific therapeutic interventions. This review presents selected PET findings that exemplify early promise in using molecular imaging to predict treatment response, provide rationale for new therapeutic targets, and monitor target engagement in biomarker-defined subtypes of psychosis. PET data, among other data types, may prove useful in the scientific pursuit of identifying precision strategies to improve clinical outcomes for individuals with psychosis.
随着医疗保健向精准医学的发展，最近对精神病患者的研究开始探索正电子发射断层扫描（PET）作为一种工具，以测试可能区分精神病亚类的生化特征，从而指导针对特定亚类的治疗干预。本综述介绍了一些 PET 研究结果，这些结果表明，分子成像在预测治疗反应、为新的治疗靶点提供依据以及监测生物标志物定义的精神病亚类中的靶点结合方面具有早期应用前景。PET 数据与其他类型的数据一起，可能有助于科学地确定精准策略，以改善精神病患者的临床结果。
